

**Performance in Delivering QTR 1 April- June 2019**

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
17/EE/0079	220827	CL010_168 A Randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of CCX168 in pts with anti-neutrophil cytoplasmic antibody (ANCA)-Associated Vasculitis	Number Agreed	2	2	Date Agreed	31/12/2018	0	04/07/2018	0	Recruitment Finished	Due to study recruitment numbers being met earlier
18/YH/0012	237184	ECZTRA 3 (ECZema TRAlokinumab trial no. 3)	Number Agreed	6	6	Date Agreed	18/08/2018	4	12/10/2018	4	Recruitment Finished	PI taken long term sickness absence, which affected reaching recruitment target
16/EM/0193	190690	The Dal-GenE trial (CARD 4843) - A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS)	Number Agreed	6	6	Date Agreed	31/10/2018	7	12/11/2018	7	Recruitment Finished	
18/SC/0210	239572	EFFICACY AND SAFETY OF PF-04965842 200 MG AND 100 MG QD MONOTHERAPY IN SUBJECTS WITH AD	Number Agreed	1	1	Date Agreed	26/11/2018	0	26/11/2018	0	Recruitment Finished	Difficult to recruit to
16/LO/1822	212944	VICTORIA - A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejec	Number Agreed	10	10	Date Agreed	31/12/2018	11	31/12/2018	11	Recruitment Finished	
16/WM/0365	210358	A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacody	Number Agreed	2	2	Date Agreed	30/09/2018	4	31/01/2019	4	Recruitment Finished	